

Bernard L. Marini, Pharm.D., BCOP

bernmari@med.umich.edu

PROFESSIONAL EXPERIENCE

- Nov 2020 – Present **Clinical Pharmacist Specialist, Hematology**
Clinical Associate Professor
University of Michigan College of Pharmacy
University of Michigan Health System, Ann Arbor, MI
- July 2014 – Nov 2020 **Clinical Pharmacist Specialist, Hematology**
Adjunct Clinical Assistant Professor
University of Michigan Health System, Ann Arbor, MI
- July 2012 – June 2014 **Clinical Pharmacist**
Adjunct Clinical Instructor
University of Michigan Health System, Ann Arbor, MI
- June 2010 – July 2012 **Ambulatory Care Pharmacy Intern**
Henry Ford Medical Center – Detroit Northwest, Detroit, MI
Preceptor: Mina Sedarous, Pharm.D.
- May 2011 – July 2011 **Managed Care Pharmacy Intern**
Blue Care Network, Southfield, MI
Preceptor: Emily DuVall, Pharm.D., MBA
- Dec 2008 – June 2011 **Community Pharmacy Intern**
Kroger Pharmacy, Richmond, MI
Preceptor: Nicole Furtah, Pharm.D.
- Sept 2008 – June 2010 **Laboratory Research Assistant**
University of Michigan Health System; D.K. Bishop Immunology Lab
- Studied chronic cardiac allograft rejection
 - Taught research methods to undergraduate students

TRAINING AND EDUCATION

- July 2013 – June 2014 **PGY2 Hematology/Oncology Pharmacy Practice Residency**
University of Michigan Health System, Ann Arbor, MI
- ASHP Accredited
 - Program Director: Shawna Kraft, Pharm.D., BCOP
- July 2012 – June 2013 **PGY1 Pharmacy Practice Residency**
University of Michigan Health System, Ann Arbor, MI
- ASHP Accredited
 - Program Director: John Clark, Pharm.D., MS, BCPS, FASHP
- Sep 2008 – May 2012 **Doctor of Pharmacy**
College of Pharmacy, University of Michigan, Ann Arbor, MI

Sep 2005 – May 2008

Bachelor of Science, Anthropology-Zoology

University of Michigan, Ann Arbor, MI

- Graduation with Highest Distinction (3 years)

PUBLICATIONS

*Pharmacy Resident/Student Trainee

Completed:

1. Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin S, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, **Marini BL**. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. *Leuk Lymphoma*. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378. Epub ahead of print. PMID: 33830856.
2. Talagtag M*, Patel TS, Scappaticci GB, Perissinotti AJ, Schepers AJ, Petty LA, Pettit KM, Burke PW, Bixby DL, **Marini BL**. Utility of methicillin-resistant *Staphylococcus aureus* (MRSA) nasal screening in patients with acute myeloid leukemia (AML). *Transpl Infect Dis*. 2021 Apr 7:e13612. doi: 10.1111/tid.13612. Epub ahead of print. PMID: 33825279.
3. Perissinotti AJ, Benitez LL, **Marini BL**. Oral Azacitidine Maintenance for Acute Myeloid Leukemia. *N Engl J Med*. 2021 Apr 1;384(13):e51. doi: 10.1056/NEJMc2101283. PMID: 33789022.
4. Ravi K*, Franson A, Homan MJ*, Roberts H, Pai MP, Miklja Z, He M, Wen B, Benitez LL, Perissinotti AJ, Bixby DL, Koschmann C, **Marini BL**. Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. *Leuk Lymphoma*. 2021 Mar 7:1-6. doi: 10.1080/10428194.2021.1894647. Epub ahead of print. PMID: 33682631.
5. Reid JH*, Perissinotti AJ, Benitez LL, Boyer D, Lee W, Burke PW, Pettit K, Bixby DL, **Marini BL**. Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts. *Leuk Res*. 2021 Apr;103:106539. doi: 10.1016/j.leukres.2021.106539. Epub 2021 Feb 19. PMID: 33647818.
6. Reid JH*, **Marini BL**, Benitez LL, Pettit K, Bixby DL, Burke P, Perissinotti AJ. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2021 Jan 19:S2152-2650(21)00019-7. doi: 10.1016/j.clml.2021.01.011. Epub ahead of print. PMID: 33612433.
7. Ochs MA*, Perissinotti AJ, **Marini BL**, Burke PW, Bixby DL, Pettit KM, Benitez LL. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. *Leuk Res*. 2021 Mar;102:106517. doi: 10.1016/j.leukres.2021.106517. Epub 2021 Jan 26. PMID: 33561633.
8. Bazzell BG*, Benitez LL, **Marini BL**, Perissinotti AJ, Phillips TJ, Nachar VR. Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2020 Dec 23:S2152-2650(20)31039-9. doi: 10.1016/j.clml.2020.12.018. Epub ahead of print. PMID: 33485834.
9. Reid JH*, Durant KM, Chen SL, Perissinotti AJ, King R, Khoriaty R, **Marini BL**. Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura [published online ahead of print, 2020 Jun 30]. *J Oncol Pharm Pract*. 2020;1078155220934862. doi:10.1177/1078155220934862
10. Miklja Z, ... **Marini BL**, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFR α -driven glioma [published online ahead of print, 2020 Jun 30]. *J Clin Invest*. 2020;133310. doi:10.1172/JCI133310

11. Reid JH*, **Marini BL**, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. *Crit Rev Oncol Hematol*. 2020;148:102897. doi:10.1016/j.critrevonc.2020.102897
12. Wierzbiicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ*, **Marini BL**, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma [published correction appears in *Curr Oncol Rep*. 2020 Apr 16;22(5):47]. *Curr Oncol Rep*. 2020;22(2):19. Published 2020 Feb 6. doi:10.1007/s11912-020-0877-0
13. Weis TM*, **Marini BL**, Nachar VR, Brown AM, Phillips TJ, Brown J, Wilcox RA, Kaminski MS, Devata S, Perissinotti AJ. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. *Leuk Lymphoma*. 2019 Dec 26;1-7. doi: 10.1080/10428194.2019.1703969. [Epub ahead of print]. PMID: 31876206.
14. Hoylman E*, Brown A, Perissinotti AJ, **Marini BL**, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. *Leuk Lymphoma*. 2019 Nov 18;1-8. doi: 10.1080/10428194.2019.1688324. [Epub ahead of print]. PMID: 31739729.
15. Reid JH*, Perissinotti AJ, Benitez L, Bixby DL, Burke P, Pettit K, **Marini BL**. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. *Leuk Lymphoma*. 2019 Nov 18;1-7. doi: 10.1080/10428194.2019.1691199. [Epub ahead of print]. PMID: 31739707.
16. Alsawah F, Benitez L, Choi S, **Marini B**, Perissinotti A, Skyles A, Burke P, Pettit K, Crouch A, Fox H, Bixby D. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. *Blood Adv*. 2019 Nov 12;3(21):3333-3336. doi: 10.1182/bloodadvances.2019000289. PMID: 31698446; PMCID: PMC6855106.
17. Merz LE, Perissinotti AJ, **Marini BL**, Burke PW, Crouch A, Erba HP, Bixby D. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. *Clin Lymphoma Myeloma Leuk*. 2019 Sep 28. pii: S2152-2650(19)32002-6. doi: 10.1016/j.clml.2019.09.615. [Epub ahead of print] PubMed PMID: 31711889.
18. Weis TM*, Perissinotti AJ, Nachar VR, Brown A, Phillips TP, **Marini BL**. Dosing vincristine in DA-EPOCH-R: to cap or not to cap? *J Clin Oncol*. 2019. *J Clin Oncol*. 2019 Sep 18;JCO1901259. doi: 10.1200/JCO.19.01259. [Epub ahead of print] PubMed PMID: 31532723.
19. **Marini BL**, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL. Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? 10 July 2019. <https://doi.org/10.1002/cncr.32381>
20. Weis TM*, **Marini BL**, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. *Crit Rev Oncol Hematol*. 2019 Jun 28;141:125-138. doi: 10.1016/j.critrevonc.2019.06.011. [Epub ahead of print]
21. Patel HP*, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, **Marini BL**. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. *Open Forum Infect Dis*. 2019 Apr 12;6(5):ofz176. doi: 10.1093/ofid/ofz176.

22. **Marini BL**, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R, Jasty Rao R, Slagle L, Bishop L, Pettit K, Bixby DL, Burke PW, Perissinotti AJ. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. *Leuk Lymphoma*. 2019 May 17:1-15. doi: 10.1080/10428194.2019.1608530. [Epub ahead of print]
23. Reid JH*, **Marini BL**, Nachar VR, Devata S, Perissinotti AJ. PET-guided, BEACOPP(escalated) therapy in advanced Hodgkin lymphoma. *Lancet Oncol*. 2019 Apr;20(4):e188. doi: 10.1016/S1470-2045(19)30081-6.
24. Chappell G, Geer M, Gatz E, Braun T, Churay T, Brisson J, Bixby D, **Marini B**, Perissinotti A, Frame D, Parkin B, Reddy P, Magenau J, Choi SW. Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. *Bone Marrow Transplant*. 2019 Feb 26. doi: 10.1038/s41409-019-0493-5. [Epub ahead of print]
25. Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhyay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, **Marini B**, Fouladi M, Parsons DW, Leary S, Mueller S, Ligon KL, Koschmann C. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. *Neuro Oncol*. 2019 Feb 26. pii: noz022. doi: 10.1093/neuonc/noz022. [Epub ahead of print]
26. Robinson AC*, **Marini BL**, Pettit KM, Perissinotti AJ. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. *J Oncol Pharm Pract*. 2019 Feb 13:1078155219829534.
27. Cheung E*, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL, Brown J, Scappaticci GB, **Marini BL**. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. *Ann Hematol*. 2019 Jan 21. doi: 10.1007/s00277-019-03606-0. [Epub ahead of print]
28. Perissinotti AJ, **Marini BL**. Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time? *Mycoses*. 2018 Nov 26. doi: 10.1111/myc.12871. [Epub ahead of print]
29. Vulaj V*, Perissinotti AJ, Uebel JR, Nachar VR*, Scappaticci GB*, Crouch A, Bixby DL, Burke PW, Maillard I, Talpaz M, **Marini BL**. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. *Leuk Res*. 2018 [published online 1 June 2018]. <https://doi.org/10.1016/j.leukres.2018.05.011>
30. Koschmann C, Wu Y, Kumar-Sinha C, Lonigro R, Vats P, Kasaian K, Cieslik M, Cao X, Frank K, Prensner J, Zurieck A, Everett J, Anderson B, **Marini B**, Camelo-Piragua S, Venneti S, McKeever P, McFadden K, Lieberman A, Leonard M, Maher C, Garton H, Muraszko K, Robertson P, Robinson D, Chinnaiyan A, Mody R. Clinically integrated sequencing significantly alters therapy in children and young adults with high-risk glial brain tumors. *JCO Precision Oncology* 2018 :2, 1-34
31. Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, **Marini BL**. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. *J Oncol Pharm Pract*. 2018 Jan 1:1078155217754244.
32. Scappaticci GB*, **Marini BL**, Nachar VR*, Uebel JR, Vulaj V*, Crouch A, Bixby DL, Talpaz M, Perissinotti AJ. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. *Ann Hematol*. 2018 Apr;97(4):573-584. doi: 10.1007/s00277-017-3217-1. Epub 2017 Dec 29.

33. Linzey JR, **Marini BL**, Pasternak A, Smith C, Miklja Z, Zhao L, Kumar-Sinha C, Paul A, Harris N, Robertson PL, Hoffman LM, Chinnaiyan A, Mody R, Koschmann C. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. *J Neurooncol*. 2017 Dec 12. doi: 10.1007/s11060-017-2708-1. [Epub ahead of print]
34. Nachar VR*, Perissinotti AJ, Scappaticci GB*, Bixby DL, **Marini BL**. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. *Leuk Res*. 2017 Dec;63:56-61. doi: 10.1016/j.leukres.2017.10.017. [Epub ahead of print]
35. Neumann DR*, **Marini BL**, Phillips TJ, Wilcox RA, Mayer TL, Brown A, Perissinotti AJ. Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. *Leuk Lymphoma*. 2017 Nov 6:1-10. doi: 10.1080/10428194.2017.1393672. [Epub ahead of print]
36. **Marini BL**, Benitez LL*, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, Lulla R, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. *Transl Res*. 2017 Oct;188:27.e1-27.e14. [Epub ahead of print]
37. Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, **Marini B**. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. *Leuk Lymphoma*. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305. [Epub ahead of print]
38. Perissinotti AJ and **Marini BL**. Real-life challenges to the use of antifungal agents in hematology patients. *Curr Fungal Infect Rep*. 2017 Oct;11: 229-241. <https://doi.org/10.1007/s12281-017-0303-8>
39. Tang LA*, **Marini BL**, Benitez L*, Nagel JL, Miceli M, Berglund C, Perissinotti AJ. Risk factors for subtherapeutic levels of posaconazole tablet. *J Antimicrob Chemother*. 2017 Oct 1;72(10):2902-2905. doi: 10.1093/jac/dkx228. [Epub ahead of print]
40. **Marini BL**, Perissinotti AJ, Bixby DL, Brown J, Burke PW. Catalyzing improvements in ALL therapy with asparaginase. *Blood Rev*. 2017 Sep;31(5):328-338. [Epub ahead of print]
41. Rausch CR*, **Marini BL**, Benitez LL*, Elias A, Burke PW, Bixby D, Perissinotti AJ. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. *Leuk Lymphoma*. 2017 Jul 18:1-8. [Epub ahead of print]
42. Linzey JR, **Marini BL**, McFadden K, Lorenzana A, Mody R, Robertson PL and Koschmann C. Identification and targeting of a novel FGFR fusion in a pediatric thalamic “central oligodendroglioma.” *npj Precision Oncology* (2017) 1:29; doi:10.1038/s41698-017-0036-8
43. Herc ES, Kauffman CA, **Marini BL**, Perissinotti AJ, Miceli MH. Daptomycin nonsusceptible vancomycin resistant *Enterococcus* bloodstream infections in patients with hematological malignancies: risk factors and outcomes. *Leuk Lymphoma*. 2017 Apr 12:1-7. [Epub ahead of print]
44. Scappaticci GB*, Perissinotti AJ, Nagel JL, Bixby DL, **Marini BL**. Risk factors and impact of *Clostridium difficile* recurrence on haematology patients. *J Antimicrob Chemother*. 2017 Feb 10.

45. Boyd AM*, Perissinotti AJ, Nagel JL, Frame DG, **Marini BL**. Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients. *J Oncol Pharm Pract*. 2017 Jan 1:1078155217731507. doi: 10.1177/1078155217731507. [Epub ahead of print]
46. Shaikh SA*, **Marini BL**, Hough SM, Perissinotti AJ. Rational use of rasburicase for the treatment and management of tumor lysis syndrome. *J Oncol Pharm Pract*. 2017 Jan 1:1078155216687152. [Epub ahead of print]
47. DasGupta RK*, **Marini BL**, Rudoni J*, Perissinotti AJ. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. *J Oncol Pharm Pract*. 2017 Jan 1:1078155217713363. [Epub ahead of print]
48. Barker JA*, **Marini BL**, Bixby D, Perissinotti AJ. Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. *J Oncol Pharm Pract*. 2016 Dec;22(6):811-815.
49. **Marini BL**, Sun Y*, Burke PW, Perissinotti AJ. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. *J Oncol Pharm Pract*. 2016 Oct 31. [Epub ahead of print]
50. Ganti BR*, **Marini BL**, Nagel J, Bixby D, Perissinotti AJ. Impact of Antibacterial Prophylaxis during Reinduction Chemotherapy for Relapse/Refractory Acute Myeloid Leukemia. *Support Care Cancer*. 2016 Oct 14. [Epub ahead of print]
51. Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, **Marini B**, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. *Oncotarget*. 2016 Aug 25. [Epub ahead of print]
52. **Marini BL**, Samanas L*, Perissinotti AJ. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. *J Oncol Pharm Pract*. 2016 Jun 29. [Epub ahead of print]
53. **Marini BL**, Markstrom D, Frame D. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. *J Oncol Pharm Pract*. 2016 Mar 11. [Epub ahead of print]
54. **Marini BL**, Wechter AR, Burke PW, Bixby D, Perissinotti AJ. Minimizing waste during preparation of blinatumomab infusions. *Am J Health Syst Pharm*. 2016 Jan 15;73(2):19-20.
55. Koselke EA, **Marini BL**, Kraft SL, Walker SC, Allore DD, Mackler ER. Implementation of and satisfaction with an outpatient oral anticancer therapy program. *J Hematol Oncol Pharm*. 2015;5(3):62-68
56. Benitez L*, Perissinotti AJ, Santarossa M*, **Marini BL**. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. *Pediatr Blood Cancer*. 2015 Jun;62(6):1115.
57. **Marini BL**, Hough SM, Gregg KS, Abu-Seir H*, Nagel JL. Risk factors for piperacillin/tazobactam-resistant gram-negative infection in hematology/oncology patients with febrile neutropenia. *Support Care Cancer*. 2015 Aug;23(8):2287-95.

58. **Marini BL**, Choi SW, Byersdorfer CA, Cronin S, Frame DG. Treatment of dyslipidemia in Allogeneic hematopoietic Stem Cell Transplant Patients. *Biol Blood Marrow Transplant*. 2015 May;21(5):809-820.
59. Huang AM, **Marini BL**, Frame D, Aronoff DM, Nagel JL. Risk factors for recurrent *Clostridium difficile* infection in hematopoietic stem cell transplant recipients. *Transpl Infect Dis*. 2014 Oct;16(5):744-50.
60. **Marini BL**, Perissinotti AJ, Huang AM, Frame DG, Kaul DR. Risk for Invasive Fungal Infections during Acute Myeloid Leukemia Induction Therapy: a True Association with Echinocandins? *Antimicrob Agents Chemother*. 2014 Aug;58(8):4988-9.
61. **Marini BL**, Funk K, Kraft MD, Fong JM, Naanos R, Stout SM, Wagner D. The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: A pilot study. *Patient Educ Couns*. 2014 Aug;96(2):264-7.
- Working together to prevent blood clots. [Online Video] University of Michigan Health System: Ann Arbor, MI; 2013. Available from:
<http://www.youtube.com/watch?v=mhDJ7MyVwGw&feature=youtu.be>
62. Spencer S, **Marini BL**, Figg WD. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. *Anticancer Res*. 2012 Jul;32(7):2391-8.
63. Faust SM, Lu G, **Marini BL**, Zou W, Gordon D, Iwakura Y, Laouar Y, Bishop DK. Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. *J Immunol*. 2009 Dec 1;183(11):7297-306.

Other Research In Process/Submitted:

1. Burke PW, **Marini BL**, Perissinotti AJ, Benitez LL, Pettit K, Bixby DL. A Time-to-Event Continual Reassessment Method (TiTE-CRM) Phase I Study of the Addition of Venetoclax to Standard Remission Induction 7+3 for Frontline Therapy in Newly Diagnosed Acute Myeloid Leukemia [Research in progress]
2. Foucar C, **Marini BL**, Perissinotti AJ, Benitez LL, Pettit K, Burke PW, Kump K, Nikolovska-Coleska Z, Bixby DL. In vitro and phase I analysis of venetoclax plus FLAG chemotherapy in secondary AML [Research in progress]
3. Benitez LL, **Marini BL**, Perissinotti AJ, et al. FLAG or HMA Induction Therapy in the Treatment of Secondary Acute Myeloid Leukemia. [Research in progress]
4. Koschmann C, **Marini BL**, Robertson P, Mody R, Parmar H, Van der spek A, Leonard M, Zhao L. A phase 2 study of dasatinib in combination with everolimus for children with gliomas harboring PDGFR/FGFR alterations. NCT03352427 [Research in progress]
5. Umemura Y, **Marini BL**, ..., Wahl D. Phase 0/1 Dose Escalation Study of Mycophenolate Mofetil Combined with Radiation Therapy in Recurrent Glioblastoma [Research in progress; UMCC 2019.192]

TEXTBOOKS / BOOK CHAPTERS

1. **Marini BL**, Perissinotti AJ, and Worden FP. *Cancer Pharmacology and Pharmacotherapy Review*. 1st ed. New York (NY): Springer Publishing Company; 2016.

ABSTRACTS AND POSTER PRESENTATIONS

1. Roberts HJ, Ravi K, **Marini BL**, Kline C, Mueller S, Koschmann C, Franson A. Targeted Agents Recommended by the CNS-TAP Tool Compared to those Selected by a Tumor Board in a Molecularly-Driven DIPG Clinical Trial. Society For NeuroOncology (SNO) Pediatric Conference 2021. Virtual Meeting.
2. Sutherland R*, Benitez LL, Perissinotti AJ, Pogue J, **Marini BL**. Bacteremia in Hematology Patients: Impact of Duration of Antibiotic Therapy on Clinical Outcomes. University of Michigan College of Pharmacy Research Forum 2021. Virtual Meeting.
3. Clark KA*, **Marini BL**, Perissinotti AJ, Benitez LL. Retrospective Evaluation of Opioid Use in the Inpatient Acute Leukemia Population. University of Michigan College of Pharmacy Research Forum 2021. Virtual Meeting.
4. Ochs MA*, Bazzell BG*, Weis TM, Stump SE, Reid JH, Buhlinger KM, Muluneh B, Benitez LL, **Marini BL**, Perissinotti AJ. Multicenter Comparison of Re-Induction Regimens in Relapsed/Refractory Ph- ALL. University of Michigan College of Pharmacy Research Forum 2021. Virtual Meeting.
5. Ochs MA*, Bazzell BG*, Weis TM, Stump SE, Reid JH, Buhlinger KM, Muluneh B, Benitez LL, **Marini BL**, Perissinotti AJ. Multicenter Comparison of Re-Induction Regimens in Relapsed/Refractory Ph- ALL. HOPA Annual Meeting 2021. Virtual Meeting
6. Bazzell BG*, Ochs MA*, Scappaticci GB, Perissinotti AJ, **Marini BL**, Ghosh M, Phillips T, Nachar VN. Comparison of Outcomes of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Chimeric Antigen Receptor (CAR) T-Cell Therapy vs. Autologous Stem Cell Transplant (ASCT). University of Michigan College of Pharmacy Research Forum 2021. Virtual Meeting.
7. Bazzell BG*, Ochs MA*, Scappaticci GB, Perissinotti AJ, **Marini BL**, Ghosh M, Phillips T, Nachar VN. Comparison of Outcomes of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Chimeric Antigen Receptor (CAR) T-Cell Therapy vs. Autologous Stem Cell Transplant (ASCT). HOPA Annual Meeting 2021. Virtual Meeting.
8. Okerberg CK*, **Marini BL**, Koschmann C, Franson A, Umemura Y, Leung D, Junck L, Pasternak A. Impact of transporter pharmacogenetics on CNS tumor response. University of Michigan College of Pharmacy Research Forum 2021. Virtual Meeting.
9. Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffith S, Olson M, Crain M, Pettit K, Burke PW, Bixby DL, **Marini BL**. Multicenter Comparison of High-Dose Cytarabine-Based Regimens Versus Liposomal Daunorubicin and Cytarabine (CPX-351) in Patients with Secondary AML. ASH 2019. Poster # 2639
10. Reid JH*, **Marini BL**, Benitez LL, Bixby DL, Burke PW, Pettit K, Perissinotti AJ. Comparison of Re-Induction Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia (AML). UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.
11. Homan M*, Perissinotti AJ, **Marini BL**, Burke PW, Bixby DL, Pettit K, Benitez LL. Outcomes in Patients with Acute Myeloid Leukemia Receiving 10-Day Decitabine with or without Venetoclax. UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.

12. Varabyeva A*, **Marini BL**, Patel TS, Perissinotti AJ, Benitez LL, Brancaccio A, Sandison K, Lo C*, Chopra V. Does CLABSI Risk Correlate with Number of Lumens in Central Venous Catheters? UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.
13. Chen Y*, Buhlinger K, Perissinotti AJ, Schepers A, Benitez LL, **Marini BL**. PEG-Asparaginase: Comparing Strategies to Beat the Clot. UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.
14. Bazzell BG*, **Marini BL**, Benitez LL, Bixby DL, Burke PW, Pettit K, Talpaz M, Perissinotti AJ. Impact of FLT3 Inhibitors in FLT3+ Acute Myeloid Leukemia (AML). UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.
15. Ochs M*, **Marini BL**, Perissinotti AJ, Benitez LL. High Dose Cytarabine Dosing in Obese Patients with Acute Myeloid Leukemia. UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.
16. Baek GT*, **Marini BL**, Perissinotti AJ, Brown A, Nachar VR. Complications with R/O-B vs. R/O-CHOP in Patients with Indolent Non-Hodgkin's Lymphoma. UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2019. Las Vegas, NV.
17. Oh M, **Marini BL**, Perissinotti AJ, Benitez LL, Burke PW, Bixby DL, Pettit KM, Abraham I, McBride A. Bayesian network meta-analysis (NMA) of complete remission without or with incomplete hematologic recovery (CR/CRi) to CPX-351, FLAG, and standard 7+3 (7+3) chemotherapy in the treatment of newly diagnosed secondary acute myeloid leukemia (AML). J Clin Oncol 37, 2019 (suppl; abstr e18514).
18. Faust SM, Lu G, **Marini BL**, McCarty DM, Bishop DK. Transient Immunosuppression and Adeno-Associated Virus Vector Gene Transfer of Programmed Death Ligand-1 (PD-L1) Prevents the Development of Chronic Cardiac Transplant Rejection. American Society of Gene and Cellular Therapy Meeting. April 2019.
19. Merz LE, Perissinotti AJ, **Marini BL**, Crouch A, Pettit K, Burke PW, Erba HP, Bixby DL. Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities - AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom. 2018 ASH Annual Meeting. Abstract 4042. Available at: <https://ash.confex.com/ash/2018/webprogram/Paper110854.html>
20. Weis T*, **Marini BL**, Nachar V, Brown J, Phillips T, Perissinotti AJ. Impact of a vincristine dose cap on the incidence of neuropathy with DA-R-EPOCH for treatment of aggressive lymphomas. UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2018. Abstract 558292
21. Reid JH*, Perissinotti AJ, Benitez L, Bixby DL, Burke PW, Pettit K, **Marini BL**. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with significant leukocytosis. UHC/Vizient Resident Poster Presentation. ASHP Midyear Clinical Meeting 2018. Abstract 543945
22. Hoylman E*, Nachar V, Perissinotti AJ, **Marini BL**, Brown A. Optimal sequencing of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. UHC/Vizient Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation. December 2018. Abstract 549231
23. Homan M*, **Marini BL**, Perissinotti AJ, Jasty R, Walling E, Burke PW, Bixby DL, Brown J. Evaluating the implementation of premedications prior to pegaspargase infusions in pediatric acute lymphoblastic leukemia patients. UHC/Vizient Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation. December 2018. Abstract 550527

24. Nachar VR*, **Marini BL**, Bixby DL, Burke PW, Perissinotti AJ. Safety, efficacy, and activity levels of attenuated-dose PEG-asparaginase in acute lymphoblastic leukemia (ALL). UHC/Vizient Resident Poster Presentation & ASHP Midyear Clinical Meeting. December 2017. Abstract 384467
25. Alegria W*, **Marini BL**, Perissinotti AJ, Bixby DL, Nagel JL. Febrile Neutropenia Antibiotic De-escalation Study in Acute Myeloid Leukemia Patients with Prolonged Neutropenia. UHC/Vizient Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation. December 2017. Abstract 392460
26. Attilio M*, Perissinotti AJ, Scappaticci GB, Frame DG, Markstrom D, **Marini BL**. Evaluation of the Effect of Plerixafor Stem Cell Mobilization on Multiple Myeloma Relapse Rates. December 2017. Abstract 391632
27. Patel HP*, Perissinotti AJ, Patel TS, **Marini BL**. Impact of Antifungal Agent Used for Prophylaxis Against Invasive Fungal Infections During Induction Therapy for Acute Myeloid Leukemia. December 2017. Abstract 387321
28. Cheung E*, McKenzie M, Benitez Colon L, **Marini BL**, Perissinotti AJ, Eschenauer G, Alaniz C, Kaye K, Patel T. Impact of Standard versus Prolonged Courses of Antibiotics for the Treatment of Uncomplicated Staphylococcus aureus Bloodstream Infections in Patients with Hematologic Malignancies. UHC/Vizient Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation. December 2017. Abstract 388306
29. Koschmann C, Wu Y, Kumar C, Lonigro R, Vats P, Kasaian K, Cieslik M, Cao X, Frank K, Presner JR, Zureick A, Everett J, Anderson B, Mullan B, **Marini BL**, Camelo-Piragua S, Venneti S, McKeever P, McFadden KA, Lieberman A, Leonard M, Maher CO, Garton HJL, Muraszko K, Robertson P, Robinson D, Chinnaiyan A, Mody R. Clinically Integrated Sequencing Significantly Alters Therapy in Children and Young Adults with High-Risk Glial Brain Tumors. *Neuro-Oncology*, Volume 19, Issue suppl_6, 6 November 2017, Pages vi187, <https://doi.org/10.1093/neuonc/nox168.757>
30. Presner JR, Anderson B, Koschmann C, Brown J, **Marini BL**, Wu YM, Vats P, Lonigro RJ, Kumar C, Robinson DR, Chinnaiyan AM, Mody RJ. Integrative Clinical Sequencing of Pediatric and Young Adults with Cancer. 16th Annual Pediatric Research Day: Precision Medicine in Pediatrics. Mar 2017. Detroit, Michigan.
31. Koschmann C, **Marini BL**, Benitez L, Wu Y, Kumar C, Lonigro R, Vats P, Cao X, Zamler D, Camelo-Piragua S, Venneti S, McKeever P, McFadden KA, Lieberman A, Shao L, Fisher-Hubbard A, Gupta A, Pritula L, Everett J, Jacobs M, McDougall R, Leonard M, Maher C, Garton H, Muraszko K, Lowenstein PR, Castro MG, Robinson D, Chinnaiyan A, Mody R. Clinically Integrated Sequencing in the Management of Children with High-Risk Brain Tumors. *Neuro-Oncology*, Volume 18, Issue suppl_6, 1 November 2016, Pages vi145–vi146, <https://doi.org/10.1093/neuonc/now212.607>
32. King RJ, Crouch A, Radojic V, **Marini BL**, Perissinotti AJ, Bixby D. Therapeutic Outcomes of Patients with Acute Erythroid Leukemia Treated with Hypomethylating Agents. *Blood*. 2016;128:5203
33. Vulaj V*, Perissinotti AJ, Uebel J, Bixby DL, **Marini BL**. Outcomes in the treatment of secondary acute myeloid leukemia: a comparison of high-dose cytarabine-based regimens vs. other induction strategies. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, Las Vegas, NV. December 2016. Abstract 242578

34. Scappaticci GB*, **Marini BL**, Bixby DL, Perissinotti AJ. Outcomes in the treatment of previously untreated elderly acute myeloid leukemia: a comparison of clofarabine versus fludarabine (FLAG). UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, Las Vegas, NV. December 2016. Abstract 235249
35. Nachar V*, **Marini BL**, Bixby DL, Perissinotti AJ. Predictors for Re-Induction Chemotherapy in Acute Myeloid Leukemia Patients with Residual Disease on Day 14 Bone Marrow Assessment. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, Las Vegas, NV. December 2016. Abstract 226365
36. Snoke A*, Perissinotti AJ, Bixby DL, **Marini BL**. Risk factors for clofarabine hepatotoxicity in patients with acute leukemia. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, Las Vegas, NV. December 2016. Abstract 239800
37. Herc ES, **Marini BL**, Perissinotti AJ, Diaz JA, Miceli MH, Kauffman CA. Daptomycin nonsusceptible (DapNS) vancomycin resistant enterococcus (VRE) bloodstream infections (BSI) in patients (pt) with hematologic malignancies (HM): Risk Factors and Outcomes. IDWeek 2016, New Orleans, LA. October 2016. Abstract 58513
38. Ganti BR*, **Marini BL**, Nagel JL, Perissinotti AJ. Antibacterial prophylaxis in relapsed/refractory acute myeloid leukemia. ASM Microbe Conference 2016, Boston, MA. June 2016
39. Early C*, **Marini BL**, Mora E, Perissinotti AJ. Pegging down risk factors for PEG-asparaginase toxicity in patients with acute lymphoblastic leukemia. Hematology Oncology Pharmacy Association (HOPA) 12th Annual Conference, Atlanta, GA. March 2016
40. Boyd A*, Perissinotti AJ, Nagel JL, Frame DG, **Marini BL**. Risk factors for cefepime-non-susceptible gram-negative infections in hematopoietic cell transplant (HCT) recipients. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, New Orleans, LA. December 2015
41. Scappaticci GB*, Perissinotti AJ, Nagel JL, **Marini BL**. Risk factors for recurrent clostridium difficile infection (rCDI) in adult hematology patients. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, New Orleans, LA. December 2015
42. Shaikh SA*, **Marini BL**, Hough SM, Perissinotti AJ. Rational use of rasburicase for the treatment and management of tumor lysis syndrome. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation, New Orleans, LA. December 2015
43. Lorge A*, **Marini BL**, Perissinotti AJ, et al. Impact of inhaled versus oral ribavirin on outcomes in high risk oncology patients with respiratory syncytial virus infections. Selected for Topical Poster Walk (Category - "Cutting edge posters in transplant ID"). Interscience Conference on Antimicrobial Agents and Chemotherapy Poster Presentation, 55th Annual Meeting. San Diego, CA. September 2015
44. Severson JA, Mackler E, **Marini BL**, Blayney DW. Association of high symptom burden with oral oncolytic agents. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. May 2015.
45. Tang L*, **Marini BL**, Nagel JL, Frame DG, Miceli M, Carver P, Perissinotti AJ. Therapeutic drug monitoring and dose adjustment of posaconazole extended release tablet. Hematology Oncology Pharmacy Association (HOPA) 11th Annual Conference, Austin, TX. March 2015

46. Severson JA, Mackler E, **Marini BL**, Blayney DW. Association of high symptom burden with oral oncolytic agents. Palliative Care in Oncology Symposium, Boston, MA. October 2014
47. **Marini BL**, Hough SM, Gregg KS, Abu-Seir H*, Nagel JL. Risk factors for piperacillin/tazobactam-resistant gram-negative infection in hematology/oncology patients with febrile neutropenia. Interscience Conference on Antimicrobial Agents and Chemotherapy Poster Presentation, 54th Annual Meeting. Washington DC. September 2014
48. Huang AM, **Marini BL**, Frame DG, Aronoff DM, Nagel JL. Risk Factors for Recurrent Clostridium difficile Infection (CDI) in Hematopoietic Stem Cell Transplant (HSCT) Recipients. Interscience Conference on Antimicrobial Agents and Chemotherapy Poster Presentation, 53rd Annual Meeting. Denver CO. September 2013.
49. **Marini BL**, Markstrom D, Frame DG. Risk of GVHD with rituximab-containing conditioning regimens in allogeneic HSCT. UHC Pharmacy Council Resident Poster Presentation and ASHP Midyear Clinical Meeting Poster Presentation. Las Vegas, NV. December 2012. Poster #8-063.
50. Fong J, Naanos R, Funk KA, **Marini BL**, Kraft MD, Wagner MD, Stout S. Evaluation of venous thromboembolism risk assessment in hospitalized adult medicine patients. ASHP Midyear Clinical Meeting. New Orleans, LA. December 2011. Poster #4-150.
51. Kraft MD, Wagner DS, Funk KA, **Marini BL**, Fong J, Naanos R, Stout S. "VTE and You": Assessment of a VTE patient education video ("InPHARMmercial") and an electronic risk scoring tool in hospitalized medicine patients. CHEST Annual Meeting. Honolulu, HI. October 2011.
52. Faust SM. Lu G, **Marini BL**, Bishop DK. Role of T Cell TGF β Signaling in Allograft Acceptance and Chronic Rejection. University of Michigan Moses Gunn 21st Annual Research Conference. Ann Arbor, MI. March 2009.

GRANT FUNDING

- | | |
|--------------|---|
| January 2020 | Flynn A, Koschmann C, Marini BL , Escolero S, Farris G, Kurosu S, Meng G, Rath B, Ravi K. Chad Carr Pediatric Brain Tumor Center Grant.
SHARING THE CNS-TAP TOOL: Implementing CNS-TAP in a Scalable, Updateable Way for Precise, Widespread Application of Drug Knowledge to Treat Diffuse Intrinsic Pontine Gliomas. <ul style="list-style-type: none"> ▪ Co-Investigator ▪ \$100,000 in funding |
| January 2019 | Marini BL , Pai A, Pasternak A, Koschmann C. HOPA 2018 Foundation Grant. Optimizing Brain Tumor Precision Medicine Therapy. <ul style="list-style-type: none"> ▪ Primary Investigator ▪ \$50,000 in funding |
| March 2018 | Koschmann C, Marini B , Robertson P, Leonard M, Mody R, Garton H, Van Der Spek A, Parmar H, Cao Y, Zhao L. UM Pediatric Brain Cancer Initiative Proof of Principal Research Collaboration (P3RC) Award: A Phase 2 Study of ONC201 for Children and Young Adults with Gliomas Harboring H3K27M Mutation <ul style="list-style-type: none"> ▪ Co-Investigator ▪ \$100,000 funding; 5% effort budgeted towards trial design/implementation/analysis |

- March 2017 –
March 2018
- Koschmann C, **Marini B**, Robertson P, Leonard M, Mody R, Garton H, Van Der Spek A, Parmar H, Cao Y, Zhao L. UM Pediatric Brain Cancer Initiative Proof of Principal Research Collaboration (P3RC) Award: A Phase 2 Study of Dasatinib in Combination with Everolimus for Children with Gliomas Harboring PDGFR/FGFR Alterations
- Co-Investigator
 - \$100,000 funding; 5% effort budgeted towards trial design/implementation/analysis

TEACHING EXPERIENCE

- Sep 2021 – Present **Clinical and Research Ethics, P412**
- Course Director
- Sep 2021 – Present **Evidence-Based Medicine, P604**
- Unit 2: Study Design and Biostatistics
- Sep 2020 – Present **Introduction to Oncology and Oncology Concepts (Elective), P637**
- Precision Medicine Lecture
- Sep 2018 – Present **M1 Immunology Discussion Leader**
- May 2015 – Present **Hematology/Oncology Fellows**
- Annual Oncopharmacology Lectures
- May 2015 – Present **PharmD Investigations Faculty Advisor**
- (2019 – Present): Alex Pierce
Project: Impact of L-carnitine use on PEG-asparaginase hepatotoxicity
 - (2019 – Present): Christabel Lo
Project: Risk factors for PICC-associated complications in acute leukemia patients
 - (2018 – Present): Jamila Sareini & Rachel Dubuisson
Project: Use of educational videos for chemotherapy education in leukemia patients
 - (2016 – 2018): Natalia Kusior & Jonathan Cohen
Project: Evaluation of acute myeloid leukemia discharge parameters and factors contributing to delayed discharge
 - (2015-2017): Kathleen Bourget
Project: Assessing the impact of a single dose of pegfilgrastim compared with daily filgrastim in patients with DLBCL on DA-EPOCH-R chemotherapy.
- May 2015 – Present **Pharmacy Student Seminar Preceptor, Fall P680/730**
- 2020: Ryan Larson, Elani Sanders
- ABCs of HLH; Core Concepts in Core Binding Factor AML
- 2019: Eunice Lee, Mrunalini Tankasala
- Precision Medicine in Acute Leukemia and Neuro-Oncology
- 2018: Christina Sudyk, Alyssa Loecher
- Precision Medicine in Oncology: A Targeted Role for Pharmacists
- 2015: Amy Montague, Ashley Soule
- Taking a BiTE out of ALL; Driving to new frontiers with CAR-T cells

July 2014 – Present

Pharmacy Residency Preceptor

Year	Rotations		Research Project		Writing Project	
2014-2015	Beejal Ganti	Laura Tang	Laura Tang	Beejal Ganti	Lisa Samanas	Jake Barker
2015-2016	Anthony Boyd Caitlin Early	Farnaz Foolad Lydia Benitez	Gianni Scappatici Caitlin Early	Anthony Boyd Suhail Shaikh	Ryan DasGupta Joslyn Neal	Lydia Benitez Yihan Sun
2016-2017	Vera Vulaj Gianni Scappaticci Allie Snoke	Deeter Neumann Casey Spitzer	Vera Vulaj Gianni Scappaticci	Victoria Nachar Allie Snoke	Deeter Neumann	Maressa Santarossa
2017-2018	Victoria Nachar Mark Attilio Heena Patel	Edna Cheung Taylor Weis	Victoria Nachar Mark Attilio Heena Patel	Will Alegria Edna Cheung	Edna Cheung	Taylor Weis
2018-2019	Taylor Weis Heena Patel Justin Reid Jola Mehmeti	Emily Hoylman Allison Lew Jefferson Cua	Taylor Weis Justin Reid Jola Mehmeti	Emily Hoylman Morgan Homan	Taylor Weis	Justin Reid
2019-2020	Justin Reid Alina Varabyeva Madeleine Ochs	Morgan Homan Andrew Tam	Justin Reid Morgan Homan Alina Varabyeva Brian Bazzell YeeAnn Chen	Grace Baek Madeleine Ochs Millicynth Talagtag	Justin Reid Morgan Homan Alina Varabyeva	Brian Bazzell Trung Ky YeeAnn Chen
2020-2021	Madeleine Ochs Brian Bazzell Carl Okerberg Mon-Yee Fung	Kaylee Clark Jacqueline Dela Pena	Madeleine Ochs Brian Bazzell Carl Okerberg	Kaylee Clark Ryan Sutherlan	Madeleine Ochs	Brian Bazzell

January 2014 – Present

Ethics/Evidence-based Medicine, Winter P545

University of Michigan College of Pharmacy, Ann Arbor, MI

- Medical Marijuana: Putting Aside Biases

June 2012 – Present

P3 IPPE and P4 APPE Preceptor

University of Michigan College of Pharmacy, Ann Arbor, MI

Jan 2017 – October 2020

M2 Hematology/Oncology Sequence

- Annual Oncopharmacology Lecture

January 2014 – June 2014

Pharmacotherapeutics, Winter P532

University of Michigan College of Pharmacy, Ann Arbor, MI

- Hematology/Oncology Lectures and Labs

June 2012 – Dec 2012

Direct Patient Care, Fall P552

University of Michigan College of Pharmacy, Ann Arbor, MI

INVITED LECTURES / PROFESSIONAL PRESENTATIONS

April 2021

Creating and Optimizing Your Digital Footprint

Rho Chi Town Hall 2021, Virtual.

April 2021

Making Headway in Precision Medicine Therapy for Pediatric Brain Tumors

HOPA Annual Conference 2021, Virtual.

April 2021	Review of Controversial Treatments in AML and ALL: Do we Incorporate into Clinical Practice? ACCME-accredited CME presentation, University of Michigan Hematology Conference, Ann Arbor, MI
Mar 2021	“Drugs for Acute Lymphoblastic Leukemia with Dr. Bernard Marini” Plenary Session Podcast Episode 3.60 https://www.plenarysessionpodcast.com/episodes/ma6d45lwqw8r655-mmbhe-zybr9-h7sab-5xr4p-gzfmz-e9zhn-n22g7-69lka-fkprh
Dec 2020	“All Recent Acute Myeloid Leukemia Drugs with Dr. Bernard Marini” Plenary Session Podcast Episode 3.27 https://www.plenarysessionpodcast.com/episodes/x3846t9sxwywced-slyf3-rstp6-685wr-sc7qw-fklz9-5zxfq-n337a-ekksn-hy5sx-mskxi-xeamp-bbijy
June 2020 - Present	HOPA BCOP Annual Preparatory and Recertification Course Speaker and Content Creator: Acute Leukemias/MDS HOPA BCOP Recertification Program <ul style="list-style-type: none">• 1 hour webinar• Top 10 Clinical Pearls podcast• Pathophysiology podcast• Comprehensive BCOP preparatory chapter (bi-annual updates)
May 2019	Updates in the Treatment of Acute Myeloid Leukemia MSHO Oncology Pharmacists Forum, Ann Arbor, MI
April 2019	Leukemia is Coming: The Battle of Targeted Therapies in AML 15 th Annual HOPA Conference, Fort Worth, TX
November 2018	A New Hope: Progress in the Treatment of AML St. Joseph Mercy Ann Arbor Oncology Grand Rounds, Ann Arbor, MI
August 2018	Making Precision Medicine in Oncology More Precise: Development of the CNS-TAP Tool for Selection of Targeted Therapies Next Generation Dx Summit: Precision Medicine, Washington, DC
March 2018	Debating the Current Paradigm in the Prophylaxis and Treatment of Invasive Mold Infections 14 th Annual HOPA Conference, Denver, CO
November 2017	Dr. StrangeDrug, or: How I Learned to Stop Worrying and Love the Asparaginase ACCME-accredited CME presentation, Leukemia Grand Rounds, University of Michigan Hospital, Ann Arbor, MI
November 2017	A New Era in Oncology: Immunotherapy ACPE-accredited CE presentation, SMSHP Awards Banquet, Southfield, MI
October 2017	Clinical Updates: Hematology/Oncology ACPE-accredited CE presentation, MSHP Annual Meeting, East Lansing, MI

- January 2017 **Leukemia & Lymphoma ASH 2016 Update (or 60 minutes on everything Anthony & Bernie decided was important)**
ACCME-accredited CME presentation, Leukemia Grand Rounds, University of Michigan Hospital, Ann Arbor, MI
- April 2016 **Debating the Current Paradigm in the Prophylaxis and Treatment of Invasive Mold Infections**
ACCME-accredited CME presentation, Leukemia Grand Rounds, University of Michigan Hospital, Ann Arbor, MI
- February 2015 –
October 2016 **A Bone-a-fide Update on Multiple Myeloma**
UMHS Hematology/Oncology Nursing Core Class Lectures, Ann Arbor, MI
- September 2014 **The Hematology PharmD: Beyond the Suit & Tie**
Leukemia Grand Rounds – Pharmacology of ALL and AML Therapies, University of Michigan Hospital, Ann Arbor, MI
- April 2014 **Risk Factors for Piperacillin/Tazobactam-Resistant Gram-Negative Infection in Hematology/Oncology Patients with Febrile Neutropenia**
Great Lakes Pharmacy Resident Conference, Purdue University, West Lafayette, IN
- March 2014 **Medication Adherence: Practical Cases with Oral Oncolytics**
MOQC Oral Oncolytics Collaborative Meeting, New Hudson, MI
- March 2014 **Principles and Management of Drug Interactions and Common Side Effects of Oral Anticancer Therapies**
ACPE-accredited CE presentation, Michigan Pharmacist Association Annual Meeting & Exposition, Detroit, MI
- February 2014 **Managing Drug Interactions with Oral Anticancer Therapies**
CME presentation, Symptom Management and Supportive Care Conference, University of Michigan Hospital, Ann Arbor, MI
- January 2014 **Updates in the Treatment of Metastatic Castration-Recurrent Prostate Cancer**
ACPE-accredited CE presentation, University of Michigan Hospital, Ann Arbor, MI
- October 2013 **Principles of Medication Reconciliation** (Series of 3 Presentations)
Workshop for Clinicians and Support Staff, University of Michigan Hospital, Ann Arbor, MI
- September 2013 **Patient Care Coordination and Self-Care Management in Practice**
MOQC Oral Chemotherapy Collaborative & Symposium, Lansing, MI
- May 2013 **Risk of GVHD with Rituximab-Containing Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation**
Great Lakes Pharmacy Resident Conference, Purdue University, West Lafayette, IN

February 2013

Bone Metastases in Cancer Patients: There's Nothing *Humerus* About it
 ACPE-accredited CE presentation, University of Michigan Hospital, Ann Arbor, MI

LEADERSHIP EXPERIENCE

July 2020 - Present	PGY2 Oncology Residency Program Director University of Michigan Hospital, Ann Arbor, MI
July 2018 – Present	Residency Advisory Committee Member University of Michigan Hospital, Ann Arbor, MI
July 2018 – June 2020	PGY2 Oncology Residency Coordinator University of Michigan Hospital, Ann Arbor, MI
July 2016 – June 2020	Resident Clinical On-Call Program Coordinator University of Michigan Hospital, Ann Arbor, MI
May 2016 – Aug 2017	Pharmacy Practice Advancement Initiative Committee Member University of Michigan Hospital, Ann Arbor, MI
July 2013 – June 2014	Chief Resident University of Michigan Hospital, Ann Arbor, MI
July 2013 – June 2014	Michigan Oncology Quality Consortium (MOQC) Lead Team University of Michigan Hospital, Ann Arbor, MI
June 2012 – June 2014	Michigan Society of Health-System Pharmacists Residency Committee Member, Ann Arbor, MI
June 2012 – May 2013	Residency Class Community Service Committee, Chair University of Michigan Hospital, Ann Arbor, MI
Feb 2012 – May 2012	P4 Pledge Drive Committee, Co-Chair University of Michigan College of Pharmacy <ul style="list-style-type: none"> Achieved record class participation: 93%
2011 – 2012	Leadership Scholars Program University of Michigan College of Pharmacy
2008 – 2012	Pharmacy Student Government Council University of Michigan College of Pharmacy <ul style="list-style-type: none"> 2009, 2011: Class Representative 2010: Vice President; Head of Honor Council

OTHER CLINICAL SERVICES

April 2018 – Present	Medication Use Evaluation Committee Member
Feb 2018 – Present	Adult CNS Precision Medicine Tumor Board
April 2015 – Present	Pediatric CNS Precision Medicine Tumor Board

July 2014 – Present	Leukemia Tumor Board Member
July 2014 – Present	Lymphoma Tumor Board Member
July 2013 – Present	Cancer Pharmacy Committee Member
Nov 2017 – Dec 2019	Michigan Medicine Cellular Immunotherapy Group Representative

PROFESSIONAL/COMMUNITY SERVICE

Oct 2019 – Present	<p>Advanced Topics for Oncology Pharmacy Professionals (ATOPP)</p> <ul style="list-style-type: none"> • Helping to plan 1st Annual Conference • Branding & Marketing Committee Member
Sep 2019 – Present	Ann Arbor Cougars Girls 10U Hockey Coach
May 2019 – Present	Annual Champions for Change ChadTough Foundation Gala, Volunteer
Mar 2018 – Present	Saline Community Education – Girls Middle School Lacrosse Coach
Nov 2012 – Present	<p>Journal Peer Reviewer</p> <ul style="list-style-type: none"> • Expert Review of Hematology • Antimicrobial Agents and Chemotherapy • F1000Research • BMC Cancer • Journal of Supportive Care in Cancer • Annals of Pharmacotherapy
Oct 2011 – Dec 2016	<p>Hope Clinic, Volunteer Ypsilanti, MI</p>
May 2013	<p>AHA Heart Walk Team Leader Ann Arbor, MI</p>
Jan 2013	<p>APhA-ASP Counseling Competition, Volunteer Patient, Case Author Ann Arbor, MI</p>
2007 – 2012	<p>Relay for Life, Team Leader (2011), Volunteer Ann Arbor, MI</p>
2009 – 2011	<p>UM College of Pharmacy Alumni Golf Outing, Volunteer Ann Arbor, MI</p>
2009 – 2011	<p>Shoot for a Cure, Volunteer Detroit, MI</p>
2009 – 2010	<p>UM College of Pharmacy P1 Orientation, Volunteer Ann Arbor, MI</p>

HONORS & AWARDS

2019	PGY2 Oncology Residency Preceptor of the Year
2019	Nominated for University of Michigan College of Pharmacy Preceptor of the Year
2018	Rho Chi / Phi Lambda Sigma Initiation Keynote Speaker
2015	Nominated for University of Michigan College of Pharmacy Preceptor of the Year
2015	UMHS Making a Difference Award (twice)
2012	Albert B. Prescott Scholarship Award (Top GPA in Class)
2011 – 2012	Gloria N. Francke Scholar (Leadership Scholars Program)
2011	University of Michigan Clinical Skills Competition (2 nd place)
2011	Alumni Award (Top GPA in Class)
2011	Inducted into Rho Chi Society
2011	Phi Delta Chi Brother of the Month Award (January)
2011	Phi Delta Chi Brother Achievement Award
2010 – 2011	Ara G. and Shirley W. Paul Scholarship
2010	ASHP National Clinical Skills Competition Participant
2010	MSHP Clinical Skills Competition (2 nd place)
2010	University of Michigan Clinical Skills Competition (1 st place)
2010	Rho Chi Award (Top GPA in Class) & Recognition Certificate
2010	Phi Delta Chi Brother Excellence Award
2009 – 2010	American Pharmacists Association UM Counseling Competition Top Ten
2009 – 2010	Dean's Scholarship Award for Highest Distinction
2008 – 2010	College of Pharmacy Academic Recognition Scholarship
2005 – 2009	Robert C. Byrd Honors Scholarship Award
2007 – 2008	Michigan Competitive Scholarship
2006 – 2008	James B. Angell Scholar (4.0 GPA, 14+ credits, 5 or more terms)
2005 – 2008	University Honors (University of Michigan LS&A)
2007	Inducted into Phi Beta Kappa Honor Society

LICENSURE AND CERTIFICATION

2017 – Present	Board Certified Oncology Pharmacist
2012 – Present	Registered Pharmacist and Controlled Substance License State of Michigan Board of Pharmacy (License No. 5302038963)
2013 – 2014	Teaching Certificate Program University of Michigan Health System
October 2013	LEAN Healthcare Course Certification

PROFESSIONAL AFFILIATIONS

2013 – Present	Hematology/Oncology Pharmacy Association
2012 – Present	Michigan Pharmacists Association
2012 – Present	Michigan Society of Health-System Pharmacists
2010 – Present	American Society of Health-System Pharmacists
2014 – 2016	American Society of Hematology